Supernus Pharmaceuticals (SUPN) EBIT Margin (2011 - 2026)
Supernus Pharmaceuticals' EBIT Margin came in at -26.46% for Q2 2026, down 33.80 percentage points from 7.34% a year earlier.
Powered by 
Analysis
Supernus Pharmaceuticals (SUPN) EBIT Margin (2011 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Supernus Pharmaceuticals reported EBIT Margin of -13.95%, down 23.60 percentage points year-over-year; for FY2025, it came in at -8.66%, down 21.00 percentage points from FY2024.
- EBIT Margin carries a five-year change of -42.04 percentage points (FY2020 to FY2025).
- Going back by year, EBIT Margin was 12.34% in FY2024 (+13.21 pp), -0.87% in FY2023 (-7.78 pp), 6.91% in FY2022 (-7.93 pp) and 14.84% in FY2021 (-18.54 pp).
- The five-year range for quarterly EBIT Margin is -31.35% (Q3 2025) to 23.25% (Q3 2024).
- Year-over-year, EBIT Margin increased in two of the last seven quarters, with an average year-over-year change of -11.77 percentage points.
- The fastest year-over-year change in EBIT Margin over five years came in Q2 2024 (a gain of 26.38 percentage points), and the weakest in Q3 2025 (a drop of 54.60 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 37.40% |
| 10 | Supernus Pharmaceuticals | 2.59 Bn | 1.25 Bn | 185.39 Mn | -26.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.46% |
| Dec 31, 2025 | -1.86% |
| Sep 30, 2025 | -31.35% |
| Jun 30, 2025 | 7.34% |
| Mar 31, 2025 | -6.85% |
| Dec 31, 2024 | 12.29% |
| Sep 30, 2024 | 23.25% |
| Jun 30, 2024 | 13.41% |
| Mar 31, 2024 | -2.20% |
| Dec 31, 2023 | -0.61% |
| Sep 30, 2023 | 5.29% |
| Jun 30, 2023 | -12.97% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | 20.52% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 6.67% |
| Mar 31, 2022 | 1.29% |
| Dec 31, 2021 | 3.83% |
| Sep 30, 2021 | 21.96% |
| Jun 30, 2021 | 24.14% |
API Access
Supernus Pharmaceuticals EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=SUPN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "SUPN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=SUPN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();